TransMedics Group, Inc. (TMDX) is a United States–based company operating in the healthcare sector, within the advanced medical devices industry. The company specializes in technologies for organ preservation, assessment and transport used in transplantation procedures.

Its portfolio includes the Organ Care System (OCS), platforms designed for heart, lung and liver preservation, as well as clinical logistics services, monitoring systems and operational support for transplant centers.

Its activities include:

• Development of organ-preservation and perfusion technologies.
• Manufacturing of medical devices for transplant procedures.
• Clinical logistics and organ-transport coordination.
• Monitoring and data management during organ preservation.
• Technical and operational support for transplant centers.

The company operates across the United States, Europe and Asia-Pacific, serving hospitals, transplant centers and healthcare institutions specialized in complex surgical procedures.

Market factors influencing its operations include demand for organ transplants, limitations in donor availability, regulatory requirements for medical devices, adoption of normothermic perfusion technologies, hospital cost structures and expansion of transplant logistics networks.

Its operating model integrates medical-device development, specialized logistics, data monitoring and clinical support, with infrastructure that includes research facilities, engineering teams and logistics operations.

TransMedics Group, Inc. is listed on the Nasdaq under the ticker TMDX.

History and Development

TransMedics was founded in 1998 in Massachusetts, driven by the development of technologies capable of maintaining organs under physiological conditions outside the human body.

In its early years, the company focused on clinical validation, system prototyping and advancements in normothermic perfusion, while building partnerships with transplant centers.

As the technology matured, TransMedics expanded internationally, developed new iterations of the OCS platform and obtained regulatory approvals across multiple regions, enabling broader commercialization.

A key milestone was its initial public offering (IPO) in 2019, which supported further expansion, product development and scaling of its clinical logistics model.

In recent years, the company has focused on expanding OCS adoption, strengthening logistics capabilities and integrating technology with clinical services, supported by growing demand for transplant procedures.